嵌合抗原受体
免疫学
内科学
细胞因子释放综合征
医学
移植
肿瘤科
免疫疗法
免疫系统
作者
Shannon L. Maude,Noelle V. Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp
标识
DOI:10.1056/nejmoa1407222
摘要
Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor–modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI